Health ❯ Healthcare ❯ Oncology

Cancer Treatment

Immunotherapy Pancreatic Cancer Chemotherapy Targeted Therapy Targeted Therapies Small Cell Lung Cancer Patient Care Antibody-Drug Conjugates Drug Development Precision Medicine

Erasca Raises $632.5M While Facing IP Challenge, Patient Death and Investor Lawsuits

Legal and safety disclosures threaten Erasca's ERAS-0015 program by increasing litigation and regulatory risk.

EMA Opens Rolling Review as U.S. Hospitals Start Early Access to Daraxonrasib

Trodelvy Approved in U.S. and EU as First‑Line Option for Metastatic Triple‑Negative Breast Cancer

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

Brazilian CAR‑T Therapy Shows 87.5% Response in Early Trial

Large Observational Studies Link GLP‑1 Drugs to Lower Cancer Rates and Slower Progression

Daraxonrasib Nearly Doubles Median Survival in Previously Treated Metastatic Pancreatic Cancer

Personalized mRNA Vaccine Halves Five‑Year Melanoma Recurrence Risk

Daraxonrasib Doubles Survival in Second‑Line Metastatic Pancreatic Cancer

EMERALD-3 Trial Shows Progression-Free Survival Win for STRIDE Plus Lenvatinib With TACE

Drug Combination Cuts Progression in Aggressive Metastatic Prostate Cancer

Saitama Children’s Hospital Panel Reviews Cluster of Neurological Injuries After Intrathecal Chemotherapy

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

Akari’s AKTX-101 Shows Preclinical Synergy With KRAS Inhibitor as Stock Soars

Boehringer’s Zongertinib Wins China Conditional Approval as ASCO Data Show Patient Benefit and Broader Activity

La Paz Rolls Out Automated Mass Spectrometry to Guide Transplant Care

Brazil Unveils Robotic Cancer Surgery Center and New Public Care Funding

Roche Launches 7-Minute Under-the-Skin Lung Cancer Shot in India

Experimental KRAS Drug Nearly Doubles Survival in Advanced Pancreatic Cancer

FDA Approves Bizengri for NRG1 Fusion Cholangiocarcinoma Under Accelerated Pathway